关键信息
-
基因名
Insulin
- 应用
-
种属
Horse
-
表达系统
E. coli
-
标签
N- GST
-
纯度
Greater than 85% as determined by SDS-PAGE.
-
蛋白编号
P01310
-
表达区间
1-30aa
-
蛋白长度
Partial
-
分子量
30.1 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
Recombinant insulin, a synthetic form of human insulin produced through recombinant DNA technology, emerged as a groundbreaking advancement in diabetes management in the late 20th century. Prior to this innovation, insulin was primarily sourced from animal pancreas, which posed several challenges, including variability in potency, allergic reactions, and ethical concerns regarding animal welfare. The development of recombinant insulin addressed these issues by allowing for a more consistent and pure product that closely mimics human insulin. Research efforts focused on cloning the human insulin gene and introducing it into bacteria or yeast, making it possible to produce insulin in large quantities. Since its introduction, recombinant insulin has revolutionized the treatment of diabetes, offering patients improved glycemic control and reduced risk of complications. Further research has continued to enhance insulin analogs, leading to the creation of long-acting and rapid-acting formulations tailored to individual patient needs. Overall, the study of recombinant insulin not only highlights significant advancements in biotechnology but also underscores the ongoing commitment to innovation in healthcare for chronic disease management.
